| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 57377-0060-01 | 57377-0060 | Testosterone,USP | Testozole | 4.0 mg/1, 60.0 mg/1 | Hormonal Therapy | Androgen/Aromatase Inhibitor | Subcutaneous | Jan 1, 2021 | In Use | ||
| 50090-1882-01 | 50090-1882 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | Feb 20, 2019 | In Use | ||
| 24724-0030-03 | 24724-0030 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jun 15, 2011 | In Use | ||
| 50742-0388-10 | 50742-0388 | Estrogens, conjugated | Estrogens, conjugated | 0.45 mg/1 | Hormonal Therapy | Estrogen | Oral | Oct 16, 2025 | In Use | ||
| 43598-0262-23 | 43598-0262 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Sep 5, 2024 | In Use | ||
| 50742-0390-10 | 50742-0390 | Estrogens, conjugated | Estrogens, conjugated | 0.9 mg/1 | Hormonal Therapy | Estrogen | Oral | Oct 16, 2025 | In Use | ||
| 67457-0920-05 | 67457-0920 | Zoledronic acid | Zoledronic acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Oct 12, 2020 | May 31, 2021 | In Use | |
| 50090-7480-02 | 50090-7480 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Dec 20, 2024 | In Use | ||
| 72162-2418-01 | 72162-2418 | Raloxifene hydrochloride | Raloxifene hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Oct 31, 2024 | In Use | ||
| 59353-0003-10 | 59353-0003 | Epoetin alfa-epbx | RETACRIT | 3000.0 [iU]/mL, 3000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Jun 18, 2018 | In Use | ||
| 55513-0148-10 | 55513-0148 | Epoetin alfa | Epogen | 4000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Aug 16, 1993 | In Use | ||
| 54868-4031-01 | 54868-4031 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | May 7, 2003 | In Use | ||
| 72162-2418-03 | 72162-2418 | Raloxifene hydrochloride | Raloxifene hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Oct 31, 2024 | In Use | ||
| 55513-0267-20 | 55513-0267 | Epoetin alfa | Epogen | 3000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Apr 14, 2025 | In Use | ||
| 00641-6174-10 | 00641-6174 | Octreotide Acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Apr 4, 2005 | In Use | ||
| 55154-0216-00 | 55154-0216 | conjugated estrogens | Premarin | 0.625 mg/1 | Hormonal Therapy | Estrogen | Oral | Jan 1, 2006 | Oct 31, 2013 | No Longer Used | |
| 00046-1102-91 | 00046-1102 | Estrogens, Conjugated | Premarin | 0.625 mg/1 | Hormonal Therapy | Estrogen | Oral | Jan 1, 2006 | In Use | ||
| 00904-3571-61 | 00904-3571 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Feb 16, 2004 | Jul 31, 2023 | No Longer Used | |
| 70771-1185-05 | 70771-1185 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan 3, 2018 | Dec 5, 2019 | In Use | |
| 00078-0342-61 | 00078-0342 | Octreotide Acetate | Sandostatin LAR Depot | Hormonal Therapy | Somatostatin Analog | Nov 1, 1988 | Aug 31, 2017 | No Longer Used | |||
| 42023-0111-01 | 42023-0111 | Estradiol Valerate | Delestrogen | 20.0 mg/mL | Hormonal Therapy | Estrogen | Intramuscular | Nov 1, 2007 | In Use | ||
| 63187-0741-30 | 63187-0741 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Oct 3, 2016 | In Use | ||
| 82448-0150-14 | 82448-0150 | Nirogacestat | OGSIVEO | 150.0 mg/1 | Ancillary Therapy | Miscellaneous Agent | Ɣ Secretase Inhibitor | Oral | Nov 27, 2023 | In Use | |
| 82448-0100-14 | 82448-0100 | Nirogacestat | OGSIVEO | 100.0 mg/1 | Ancillary Therapy | Miscellaneous Agent | Ɣ Secretase Inhibitor | Oral | Nov 27, 2023 | In Use | |
| 82448-0050-18 | 82448-0050 | Nirogacestat | OGSIVEO | 50.0 mg/1 | Ancillary Therapy | Miscellaneous Agent | Ɣ Secretase Inhibitor | Oral | Nov 27, 2023 | Jan 2, 2025 | In Use |
Found 12250 results — Export these results
Home